Black Diamond Therapeutics, Inc. announced the completion of an oversubscribed Series B financing of $85 million co-led by New Enterprise Associates and RA Capital Management. Additional new investors NexTech Invest, The Invus Group and Perceptive Advisors joined founding investor Versant Ventures in the round. In connection with the Series B round, NEA's Ali Behbahani, M.D., and RA Capital's Rajeev Shah joined the company's board of directors. They join existing board members Dr. Epstein and Versant's Brad Bolzon, Ph.D., and Alex Mayweg, Ph.D.